Abstract
Abstract Based on the results of a phase I clinical trial announced at the 2012 Symposium on Molecular Targets and Cancer Therapeutics, an antibody—drug conjugate targeting prostate-specific membrane antigen may be an effective treatment for metastatic, hormone-refractory prostate cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
